Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
FAQ
- What is Rapport Therapeutics, Inc.'s D&A?
- Rapport Therapeutics, Inc. (RAPP) reported D&A of $212K in Q2 2026.
- How has Rapport Therapeutics, Inc.'s D&A changed year-over-year?
- Rapport Therapeutics, Inc.'s D&A decreased by 15.9% year-over-year, from $252K to $212K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Rapport Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude